摘要
目的评价胸腺五肽配合化疗治疗中晚期胃癌的疗效。方法将38例中晚期胃癌患者随机分为胸腺五肽+化疗组(A组)和单纯化疗组(B组),分别观察用药前后血常规、肝功能以及T细胞亚群、自然杀伤细胞(NK细胞)及补体C3水平变化。结果A组可以明显改善患者的症状,很好地预防和减少化疗后白细胞下降、血小板减少等一系列骨髓抑制现象,经胃镜、全消化道钡餐、CT检查显示,肿瘤有不同程度的缩小,患者的细胞免疫功能明显提高,NK细胞活性提高(P<0.01),C3水平升高,疗效明显优于B组。结论胸腺五肽+化疗在中晚期胃癌治疗中是一种安全、可靠的免疫增强剂。
Objective To investigate the curative effect of thymopentin-5 （TP-5） for chemotherapeutical patients with end-stage gastric carcinoma. Methods 38 cases with end- stage gastric carcinoma were divided randomly into two groups： group A （chemotherapeutics plus TP-5） and group B （chemotherapeutics only）,and the hemogram,liver function,T lymphocyte subgroups,NK cells,and C3 of pre- and post- treatment were observed. Results Chemotherapeutics plus TP- 5 could obviously improve the clinical presentation,prevent and reduce the suppression of bone marrow function. TP- 5 also could enhance the active function of NK cells and promote the level of C3. The difference between the group A and B was significant. Conclusion The immunoenhancement of TP- 5 for chemotherapeutical patients with end- stage gastric carcinoma is safe and credible.
出处
《中国药业》
CAS
2007年第9期50-51,共2页
China Pharmaceuticals
关键词
胸腺五肽
中晚期胃癌
化疗
免疫功能
thymopentin - 5
end - stage gastric carcinoma
chemotherapy
immunity
